GC Biopharma Corp. (KRX:006280)

Market Cap	1.53T
Revenue (ttm)	1.93T
Net Income (ttm)	56.34B
Shares Out	11.41M
EPS (ttm)	4,929.94
PE Ratio	27.24
Forward PE	22.69
Dividend	1,500.00 (1.16%)
Ex-Dividend Date	Dec 27, 2024

Volume	45,225
Average Volume	55,927
Open	130,600
Previous Close	129,700
Day's Range	130,400 - 135,300
52-Week Range	111,800 - 180,300
Beta	0.91
RSI	53.04
Earnings Date	Nov 14, 2025

About GC Biopharma

GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; Kenhancer plaster for anti-inflammatory; and Zenol Cool Type and Zenol Mild Hot Type drugs to treat anti-inflammatory and pain relief. The company also offers Albumin-GCC injection (inj.) for hypoalbuminemia and shock in acute hemorrhage, as well as low synthesis of albumin; Antithrombin-III (AT-III) inj. for heredit...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1967
• Employees: 2,042
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 006280

Financial Performance

In 2024, GC Biopharma's revenue was 1.68 trillion, an increase of 3.27% compared to the previous year's 1.63 trillion. Losses were -26.28 billion, -1.32% less than in 2023.